Cerebral: Prescribing Admissions, a Dismissed Qui Tam and Consumer Refunds

In the Cerebral fraud case, the company agreed to proposed consumer relief of $5,087,253 over privacy and subscription practices. A separate qui tam alleged a reimbursement offer tied to stimulant prescriptions. Cerebral later admitted to prescribing targets and per-prescription payments in a criminal non-prosecution agreement. For someone who worked on prescribing, refills or subscriptions, the important detail is what the business paid people to do.

Cerebral sold online mental health treatment through subscriptions that gave customers access to therapists, counselors, coaches and medication prescribers. That business put clinical decisions beside recurring revenue: a patient needed care, a clinician decided whether to prescribe, and the platform collected subscription payments.

Cerebral’s Qui Tam Alleged a Prescription Quota

A former nurse practitioner at Cerebral Medical Group brought the False Claims Act complaint against Cerebral Inc. and Cerebral Medical Group, P.A. She alleged that the company offered to reimburse her Drug Enforcement Administration certification cost if she wrote enough stimulant prescriptions for ADHD.

The alleged bargain rewarded the number of prescriptions, not the quality of care:

The complaint alleged that the offer reached beyond the prescription itself. It linked the alleged inducement to claims for medication, subscriptions, mental health appointments and medication-management visits paid by federal health insurance programs. The complaint identified Medicare, Medicaid and TRICARE among the programs paying for subscriptions, which it priced at $85 to $325 a month.

The nurse practitioner also described changes in the work. According to her complaint, Cerebral increased her scheduled subscriber visits from ten hours a week to 25 to 28 hours after she obtained DEA certification. It scheduled new patients for 30 minutes and follow-ups for 15 minutes.

The screening process changed too. She alleged that prescribers initially administered an ADHD diagnostic quiz during the video visit. Her complaint described the change:

Those allegations connect the scheduling system, the diagnostic questionnaire and the reimbursement offer to the same prescribing decision. The complaint alleged that federal programs paid many tens of thousands of claims, amounting to millions of dollars, for treatment induced by the scheme. In her account, taxpayers paid for care shaped by a prescribing incentive.

The Whistleblower Dismissed the Case

The government declined to join the Cerebral qui tam, and the nurse practitioner voluntarily dismissed it in November 2023. The later corporate prescribing admissions came through a separate agreement with criminal prosecutors.

Cerebral Admitted Prescription Targets and Payments

Under its November 1, 2024 criminal non-prosecution agreement, Cerebral admitted to a 95% prescription target for initial medication-management visits.

A separate ADHD initiative sought stimulant prescribing near 100% for patients without another coexisting condition. Internal data for November 2021 showed that 52.7% of 2,128 clients in that group received stimulants.

The agreement also records that the initial-visit prescribing metric did not improve after December 2021 despite pressure. An internal analysis attributed additional prescribing to the ADHD campaign. It gives an insider a specific analysis to explain: which patients it counted, what prescribing activity it measured and how management used the result. The separate criminal case involving Done also concerned prescribing pressure and automatic refills, according to the Justice Department’s account of the trial evidence.

What the Prescribing Payments Bought

The criminal agreement describes per-prescription payments to staff it called “Out of Office R.N.s”: $10 for noncontrolled drugs and $25 for controlled substances. It separately describes payments for checking prescription-monitoring databases for ADHD stimulant prescriptions.

Cerebral also admitted offering a one-time $900 recruitment incentive tied to DEA authority and roughly 100 to 300 initial appointments. Few, if any, recruits met the conditions. That hiring offer counted appointments. The reimbursement offer alleged in the nurse practitioner’s complaint counted stimulant prescriptions.

For a prescriber or payroll employee, the difference matters. The compensation terms show what triggered payment. Encounter and prescription records show what the clinician actually did to earn it.

A Refusal Could Lead to Another Prescriber

The same criminal agreement documents thousands of duplicate accounts and provider reassignment after stimulant refusals. Those admissions bring the platform’s account handling into the prescribing story. A clinician could decline a stimulant while the patient moved to another provider.

The account history can connect those decisions: the refusal, the reassignment and what happened next. Someone who handled the transfer may know a part of the story that the original prescriber never saw.

Cerebral Consumer Refunds Followed Cancellation Complaints

The Federal Trade Commission reported on May 8, 2025 that more than $5 million in refunds were being sent to 40,249 consumers over cancellation practices.

The federal consumer complaint raised allegations about privacy representations, sensitive-data disclosures, security and subscription cancellation. Cerebral’s April 15, 2024 stipulation provided for the proposed consumer relief and a civil penalty with part of it conditionally suspended.

The subscription mechanics are particularly clear in New York’s separate December 28, 2023 announcement. The attorney general’s investigation found that Cerebral told subscribers to cancel by email, then required additional steps such as a survey. The company could cancel with a button, but used the delay to make retention offers. When that delay crossed a billing date, the customer paid for another month.

The investigation also found that Cerebral charged for treatment even when no providers were available. New York’s agreement required $540,162 in restitution for 16,552 consumers and $200,000 in penalties. The affected consumers included people charged after requesting cancellation and people who canceled without ever meeting a provider.

For a subscription employee, the cancellation request, retention messages and next charge tell the story. The customer had asked to leave. The billing continued.

What Evidence Is Needed to Prove Fraud?

For prescribing-related healthcare fraud, we connect the incentive, clinical decision and resulting claim. Cerebral’s complaint and admissions make those connections concrete: compensation terms, appointment schedules, questionnaire changes, prescription logs, duplicate accounts and provider reassignment. The payer and the service charged belong beside them.

The business records explain why. A subscription charge, a completed encounter and a prescription are separate events. An invoice and revenue ledger show what the business collected. The encounter log and clinician payment record show the work and its compensation. We examine how those records fit together and who controlled the decisions on the platform and in the medical group.

The 2024 Rutgers University Law Review analysis Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud identifies a practical information advantage: companies hold their own records and understand their own billing processes. It also points to companies’ internal analyses as evidence connecting incentives to claims. An insider who understands those systems can explain what a prescription-rate report counted, how a payment was triggered and where the resulting bill went.

That is the value of knowing the operation. A prescribing target has a patient population behind it. A payment has a condition attached. An account transfer has a history. We work with the people who can explain those details and connect them to the government money at issue.

How Much of a Settlement Does a Whistleblower Get?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We assess the prescribing and payment evidence with you to identify the whistleblower case your information can support.

You Know How the Platform Worked

If you know how prescribing targets, refill payments or account reassignment worked at Cerebral or another telehealth platform, speak to our whistleblower experts about what happened. Our work connects your account of prescribing incentives to government billing, building a case with you for telehealth fraud whistleblower lawyers. We stay beside you from that first account of the operation through the pursuit of a recovery.